Gregory M. Laird

5.6k total citations · 2 hit papers
29 papers, 1.8k citations indexed

About

Gregory M. Laird is a scholar working on Virology, Infectious Diseases and Immunology. According to data from OpenAlex, Gregory M. Laird has authored 29 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Virology, 20 papers in Infectious Diseases and 10 papers in Immunology. Recurrent topics in Gregory M. Laird's work include HIV Research and Treatment (22 papers), HIV/AIDS drug development and treatment (13 papers) and HIV/AIDS Research and Interventions (11 papers). Gregory M. Laird is often cited by papers focused on HIV Research and Treatment (22 papers), HIV/AIDS drug development and treatment (13 papers) and HIV/AIDS Research and Interventions (11 papers). Gregory M. Laird collaborates with scholars based in United States, Netherlands and Tanzania. Gregory M. Laird's co-authors include Robert F. Siliciano, Janet D. Siliciano, Christine M. Durand, C. Korin Bullen, S. Alireza Rabi, Daniel I. S. Rosenbloom, Jun Lai, Evelyn E. Eisele, Alyssa R. Martin and Alison L. Hill and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Gregory M. Laird

24 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

2014 391 citations C. Korin Bullen, Gregory M. Laird et al. Nature Medicine profile →
Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations

2015 308 citations Gregory M. Laird, C. Korin Bullen et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Gregory M. Laird

Since Specialization

Citations

This map shows the geographic impact of Gregory M. Laird's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory M. Laird with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory M. Laird more than expected).

Fields of papers citing papers by Gregory M. Laird

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory M. Laird. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory M. Laird. The network helps show where Gregory M. Laird may publish in the future.

Co-authorship network of co-authors of Gregory M. Laird

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory M. Laird. A scholar is included among the top collaborators of Gregory M. Laird based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory M. Laird. Gregory M. Laird is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interleukin-2 is a potent latency reversal agent in people with treated HIV-1 2025 ·Science Advances ·Michael L. Freeman, Brian Clagett, Konstantin Leskov, Daniela Moïsi, George A. Yendewa, Scott F. Sieg, Gregory M. Laird, Jonathan Karn, Jeffrey M. Jacobson, Benigno Rodríguez, Michael M. Lederman	0
2	A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients 2025 ·International Journal of Molecular Sciences ·Li‐Jen Chang, Michael T. Yin, Gregory M. Laird, Kristen D. Ritter, Jayesh Shah, Asim K. Debnath	0
3	SIV Env RhmAbs + N-803 at ART initiation prolongs viral decay without disrupting reservoir establishment in SIV-infected infant macaques 2025 ·PLoS Pathogens ·(unknown), (unknown), (unknown), (unknown), (unknown), Alison L. Hill, Sherrie Jean, Jennifer Wood, (unknown), Shan Liang, Gregory M. Laird, Rosemarie D. Mason, Mario Roederer, Jeffrey T. Safrit, Maud Mavigner, Ann Chahroudi	0
4	Galectin 9 Levels as a Potential Predictor of Intact HIV Reservoir Decay 2024 ·The Journal of Infectious Diseases ·Sergio Serrano‐Villar, (unknown), Peter Bacchetti, Rebecca Hoh, Clara Di Germanio, Lillian B. Cohn, Timothy J. Henrich, Peter W. Hunt, Gregory M. Laird, Satish K. Pillai, Steven G. Deeks, Michael J. Peluso	2
5	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA 2020 ·Proceedings of the National Academy of Sciences ·Francesco R. Simonetti, Jennifer A. White, Camille Tumiotto, Kristen D. Ritter, Mian Cai, Rajesh T. Gandhi, Steven G. Deeks, Bonnie J. Howell, Luis J. Montaner, Joel N. Blankson, (unknown), Gregory M. Laird, Robert F. Siliciano, John W. Mellors, Janet D. Siliciano	60
6	Differential decay of intact and defective proviral DNA in HIV-1–infected individuals on suppressive antiretroviral therapy 2020 ·JCI Insight ·Michael J. Peluso, Peter Bacchetti, Kristen D. Ritter, Subul Beg, Jun Lai, Jeffrey N. Martin, Peter W. Hunt, Timothy J. Henrich, Janet D. Siliciano, Robert F. Siliciano, Gregory M. Laird, Steven G. Deeks	124
7	Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103 ⁺ and Gut CD4 ⁺ T Cells 2020 ·Journal of Virology ·Steven A. Yukl, Shahzada Khan, (unknown), Martin Trapečar, (unknown), Guorui Xie, Sushama Telwatte, Daniel Fulop, Alexander R. Pico, Gregory M. Laird, Kristen D. Ritter, Norman G. Jones, Chuanyi M. Lu, Robert F. Siliciano, Nadia R. Roan, Jeffrey M. Milush, Ma Somsouk, Steven G. Deeks, Peter W. Hunt, Shomyseh Sanjabi	5
8	Intact proviral DNA levels decline in people with HIV on antiretroviral therapy 2019 ·Journal of Virus Eradication ·Joshua C. Cyktor, Rajesh T. Gandhi, Ronald J. Bosch, Hanna Mar, Gregory M. Laird, Bernard Macatangay, Joseph J. Eron, Robert F. Siliciano, Deborah K. McMahon, John W. Mellors	2
9	Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir 2018 ·Retrovirology ·Zheng Wang, Francesco R. Simonetti, Robert F. Siliciano, Gregory M. Laird	52
10	Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection 2017 ·Immunity ·Liang Shan, Kai Deng, Hongbo Gao, Sifei Xing, Adam A. Capoferri, Christine M. Durand, S. Alireza Rabi, Gregory M. Laird, Michelle Kim, Nina N. Hosmane, Hung‐Chih Yang, Hao Zhang, Joseph B. Margolick, Linghua Li, Weiping Cai, Ruian Ke, Richard A. Flavell, Janet D. Siliciano, Robert F. Siliciano	132
11	Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro 2015 ·AIDS ·Maame Efua Sampah, Gregory M. Laird, Joel N. Blankson, Robert F. Siliciano, Jenell S. Coleman	15
12	Role of autophagy genetic variants for the risk of Candida infections 2014 ·Medical Mycology ·Diana C. Rosentul, Theo S. Plantinga, Marius Fărcaş, Marije Oosting, Omar JM Hamza, William K. Scott, Barbara D. Alexander, (unknown), Gregory M. Laird, Leo A. B. Joosten, J.W.M. van der Meer, John R. Perfect, Bart Jan Kullberg, André van der Ven, Melissa D. Johnson, Mihai G. Netea	17
13	New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo breakdown → 2014 ·Nature Medicine ·C. Korin Bullen, Gregory M. Laird, Christine M. Durand, Janet D. Siliciano, Robert F. Siliciano	391
14	Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay 2013 ·PLoS Pathogens ·Gregory M. Laird, Evelyn E. Eisele, S. Alireza Rabi, Jun Lai, (unknown), Joel N. Blankson, Janet D. Siliciano, Robert F. Siliciano	180
15	A Novel PCR Assay for Quantification of HIV-1 RNA 2013 ·Journal of Virology ·Liang Shan, S. Alireza Rabi, Gregory M. Laird, Evelyn E. Eisele, Hao Zhang, Joseph B. Margolick, Robert F. Siliciano	73
16	A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides 2013 ·Journal of Antimicrobial Chemotherapy ·Gregory M. Laird, Evelyn E. Eisele, S. Alireza Rabi, Daria Nikolaeva, Robert F. Siliciano	36
17	Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance 2013 ·Journal of Clinical Investigation ·S. Alireza Rabi, Gregory M. Laird, Christine M. Durand, Sarah B. Laskey, Liang Shan, Justin R. Bailey, (unknown), Richard D. Moore, Robert F. Siliciano	108
18	Genetic Variation in the Dectin-1/CARD9 Recognition Pathway and Susceptibility to Candidemia 2011 ·The Journal of Infectious Diseases ·Diana C. Rosentul, Theo S. Plantinga, Marije Oosting, William K. Scott, Digna R. Velez Edwards, P. Brian Smith, Barbara D. Alexander, John C. Yang, Gregory M. Laird, Leo A. B. Joosten, J.W.M. van der Meer, John R. Perfect, Bart Jan Kullberg, Mihai G. Netea, Melissa D. Johnson	62
19	Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study 2011 ·Clinical Infectious Diseases ·Melissa D. Johnson, Theo S. Plantinga, Esther van de Vosse, Digna R. Velez Edwards, P. Brian Smith, Barbara D. Alexander, John C. Yang, Dennis Kremer, Gregory M. Laird, Marije Oosting, Leo A. B. Joosten, J.W.M. van der Meer, Jaap T. van Dissel, Thomas J. Walsh, John R. Perfect, Bart Jan Kullberg, William K. Scott, Mihai G. Netea	60
20	The deployment of an innovative real-time radiological soil characterization system 2000 ·University of North Texas Digital Library (University of North Texas) ·David F. Allen, (unknown), Gregory M. Laird, (unknown), (unknown), Robert Janke	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact